This database contains 57 studies, archived under the term: "Spain"
Click here to filter this large number of results.
Effectiveness of a psychoeducational intervention program in the reduction of caregiver burden in Alzheimer’s disease patients’ caregivers
Martín-Carrasco, Manuel,
Martín, Manuel Franco,
Valero, Carmelo Pelegrín,
Millán, Pedro Roy,
García, Celso Iglesias,
Montalbán, Salvador Ros,
Vázquez, Ana Luisa Gobartt,
Piris, Sonia Pons,
Vilanova, Montserrat Balañá
Objectives: Caregivers of patients with Alzheimer’s disease (AD) experience physical and psychological stress due to the caring experience. This study evaluated the benefits of a Psychoeducational Intervention Program (PIP) on caregiver burden in southern Europe.; Methods: A multicentre, prospective, randomised study was conducted. One hundred and fifteen caregivers of patients with clinical diagnosis of AD […]
Vitamin E paradox in Alzheimer’s disease: it does not prevent loss of cognition and may even be detrimental
Lloret, Ana,
Badía, Mari-Carmen,
Mora, Nancy J.,
Pallardó, Federico V.,
Alonso, Maria-Dolores,
Viña, Jose
There is controversy as to whether vitamin E is beneficial in Alzheimer’s disease (AD). In this study, we tested if vitamin E prevents oxidative stress and loss of cognition in AD. Fifty-seven AD patients were recruited and divided in two groups: placebo or treated with 800 IU of vitamin E per day for six months. […]
Reduced TNF-α and increased IGF-I levels in the serum of Alzheimer’s disease patients treated with the neurotrophic agent cerebrolysin
Alvarez, X. Anton,
Sampedro, Carolina,
Cacabelos, Ramon,
Linares, Carlos,
Aleixandre, Manuel,
García-Fantini, Manuel,
Moessler, Herbert
According to current scientific knowledge, excess tumour necrosis factor-α (TNF-α) and low insulin-like growth factor-I (IGF-I) are pathogenic-risk factors that constitute therapeutic targets for Alzheimer’s disease (AD). Changes in serum TNF-α, total and dissociable IGF-I levels were determined by ELISA in 207 AD patients completing a 24-wk, double-blind, placebo-controlled trial to evaluate the effects of […]
Safety and efficacy of galantamine (Reminyl) in severe Alzheimer’s disease (the SERAD study): a randomised, placebo-controlled, double-blind trial
Burns, Alistair,
Bernabei, Roberto,
Bullock, Roger,
Cruz Jentoft, Alfonso J.,
Frölich, Lutz,
Hock, Christoph,
Raivio, Minna,
Triau, Eric,
Vandewoude, Maurits,
Wimo, Anders,
Came, Elizabeth,
Van Baelen, Bart,
Hammond, Gerry L.,
van Oene, Joop C.,
Schwalen, Susanne
Background: The efficacy of galantamine has been shown in patients with mild, moderate, and advanced moderate Alzheimer’s disease (AD). Here we report its efficacy in patients with severe AD.; Methods: Between December, 2003, and March, 2007, patients aged 84 (SD 6) years with severe AD (mini-mental state examination [MMSE] score 5-12 points), in a nursing […]
Prevalence of anosognosia in Alzheimer’s disease
Turró-Garriga, Oriol,
Conde-Sala, Josep Lluís,
Reñé-Ramírez, Ramón,
López-Pousa, Secundino,
Gascón-Bayarri, Jordi,
Garre-Olmo, Josep
Background and Objective: Anosognosia is a disorder that affects the clinical presentation of Alzheimer’s disease (AD), increasing in frequency with the evolution of AD. The objective was to determine the prevalence of anosognosia and analyze the associated factors and predictors.; Patients and Method: Multicenter transversal and observational study of 345 AD patients. Anosognosia was assessed […]